Analysts Question Sun Pharma’s Future Investment Plans As Former CFO Invests In Telenor
This article was originally published in PharmAsia News
Executive Summary
Analysts are divided on whether Sudhir Valia’s investments in Telenor’s new India joint venture may prove to be a backdoor way to indirectly channel funds from Sun Pharma.
You may also be interested in...
A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?
MUMBAI - Earlier this month when Piramal Healthcare Ltd.'s Chairman Ajay Piramal announced a foray into the financial services sector, local pharma watchers were reminded of the much-touted "game-changing" deal that the scion of Ranbaxy Laboratories Ltd. Malvinder Singh struck with Daiichi Sankyo three years ago
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.